By Sabela Ojea
New York Attorney General Letitia James has secured a five-year agreement with Denmark-based Novo Nordisk to cap the price of insulin at $35 per month for uninsured New Yorkers.
Letitia James’s office deal includes the right for New Yorkers to be informed about this insulin cap by pharmacies before they buy it.
The agreement comes four months after James’s office secured the same deal with Eli Lilly and Sanofi.
Leading insulin makers Eli Lilly, Novo Nordisk and Sanofi have sharply increased list prices over the past two decades.
In March, Novo said it would cut the U.S. list prices for several insulin drugs by up to 75% amid pressure to curb diabetes-treatment costs.
A provision from earlier this year under the Inflation Reduction Act capped Medicare patients’ copays or other out-of-pocket spending on insulin at $35 a month.
Write to Sabela Ojea at [email protected]
Read the full article here
